Aurobindo Pharma Ltd
AUROPHARMA price chart
Daily close · 5-year history
Instrument details
Identifiers & classification
- Symbol
- AUROPHARMA
- MB Code
- MBEQU2615
- ISIN
- INE406A01037
- BSE code
- 524804
- Industry group
- Pharmaceuticals & Biotechnology
- Screener
- View peers →
Latest earnings
Most recent declared quarter
- Quarter
- Mar 2026
- Revenue
- 8853.34 Cr
- Net profit
- 920.84 Cr
- EPS
- 15.86
- YoY revenue
- +5.62%
Company documents
12 PDFs across 4 categories
Audited annual reports & financial statements
Earnings call transcripts & Q&A
Investor decks & strategy updates
Exchange filings & corporate announcements
Corporate timeline
Earnings, news & corporate actions for AUROPHARMA
Aurobindo Pharma shares fell nearly 9% after weak US business and Q1 results that missed estimates, raising concerns over near-term earni…
Aurobindo Pharma fell over 5% on May 22 after Q4 profit rose 2% to ₹920.84 crore, but EBITDA dropped 5% and margin shrank to 19.2%, missi…
EPS 15.86 vs est. 16.74
Missed estimates by 5.28%
Buyback up to ₹1,475 per share
Tender Offer · ₹800 Cr aggregate
USFDA inspection found severe contamination and data-integrity failures at Aurobindo Pharma's manufacturing sites, citing lapses in envir…
Aurobindo Pharma reported Q3 earnings on February 10, 2026, with revenue rising 8.4% YoY to ₹8,646 crore, surpassing estimates. Net profi…
EPS 16.80 vs est. 15.86
Beat estimates by 5.91%
Aurobindo Pharma could see a significant boost in EBITDA for FY 2027 due to the DGFT's decision to impose a Minimum Import Price on Pen-G…
Price returns
Historical performance
Technicals
Indicator consensus